Efficacy, tolerability and barriers to the use of anti-CGRP medications among migraine patients in Egypt: real world experience - Takeaways - MDSpire

Efficacy, tolerability and barriers to the use of anti-CGRP medications among migraine patients in Egypt: real world experience

  • By

  • Taha, Nourhan Abdelmohsen

  • Gomaa, Manar Abdelazeem

  • Helmy, Shahinaz Mohamed

  • Farag, Sherien Mohamed

  • Moustafa, Ramez Reda

  • June 3, 2026

  • 0 min

Share

  • 1

    The study evaluated the effectiveness and tolerability of anti-CGRP therapies in migraine patients in Egypt since their introduction in 2019.

  • 2

    Among 80 patients treated with anti-CGRP therapies, 68% experienced a favorable response with significant reductions in migraine frequency and severity.

  • 3

    Tolerability of anti-CGRP therapies was generally favorable, but treatment discontinuation occurred in 35 patients due to various reasons.

  • 4

    Relapse occurred in 42.1% of patients who discontinued treatment, highlighting the importance of ongoing management.

  • 5

    The study underscores challenges in treatment access and adherence, indicating a need for further controlled research in this area.

Original Source(s)

Efficacy, tolerability and barriers to the use of anti-CGRP medications among migraine patients in Egypt: real world experience

  • by Taha, Nourhan Abdelmohsen, Gomaa, Manar Abdelazeem, Helmy, Shahinaz Mohamed, Farag, Sherien Mohamed, Moustafa, Ramez Reda

  • June 3, 2026

Related Content

Evaluation of the Safety and Effectiveness of Calcitonin Gene-Related Peptide Antagonists in Treating Cluster Headaches: A Systematic Review and Meta-Analysis

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

Editorial: Vestibular migraine: pathophysiology, diagnosis, and management